MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Vertex Pharmaceuticals Incorporated Operating Cycle 2011-2026 | VRTX
Annual Operating Cycle Vertex Pharmaceuticals Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 375 | 284 | 229 | 190 | 177 | 156 | 167 | 168 | 205 | 178 | 235 | 241 | 65.4 | 74 | 557 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 557 | 65.4 | 220 |
Quarterly Operating Cycle Vertex Pharmaceuticals Incorporated
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 463 | - | 401 | 377 | 379 | - | 288 | 271 | 264 | - | 242 | 225 | 228 | - | 88.3 | 85.9 | 181 | - | 173 | 173 | 187 | 176 | 190 | 192 | 172 | 124 | 177 | 174 | 195 | 136 | 150 | 158 | 200 | 161 | 184 | 190 | 215 | 39.9 | 44.3 | 42.5 | 43 | 38 | 51.8 | 97.6 | 83.5 | 48 | 38.7 | 50.1 | 62.2 | 22.2 | 35.2 | 25.1 | 31.8 | 39.1 | 38.9 | 31.2 | 33.9 | 29.7 | 25.4 | 146 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 463 | 22.2 | 144 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Coherus BioSciences
CHRS
|
656 | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
1.94 K | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
237 | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 7.47 | -4.6 % | $ 205 M |  Israel |
 |
Eton Pharmaceuticals
ETON
|
189 | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Exelixis
EXEL
|
140 | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
325 | $ 2.41 | 4.78 % | $ 67.2 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | Britain |
 |
AbCellera Biologics
ABCL
|
173 | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.63 | 2.52 % | $ 434 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
349 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Gilead Sciences
GILD
|
160 | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
3.28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.12 | - | $ 649 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |